Project 1: TQB3616 in Combination with Fulvestrant for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: A Randomized, Double-blind, Parallel-controlled Phase Ⅲ Clinical Trial
殷咏梅 江苏省人民医院妇幼分院副院长
YIN Yongmei , Associate Dean,&,,Jiangsu Province Hospital
14:20 - 14:40
华领医药技术（上海）有限公司
HUA Medicine (Shanghai）Ltd.
项目2：多格列艾汀片改善β细胞葡萄糖敏感性的临床研究
Project 2: Clinical Study of Dorzagliatin Tablets on Improving Beta-cellGlucose Sensitivity
陈力 华领医药技术（上海）有限公司首席执行官
CHEN Li , CEO of Hua Medicine (Shanghai) Co., Ltd.
14:40 - 15:00
武汉禾元生物科技股份有限公司
Wuhan Healthgen Biotechnology Corp.
项目3：植物源重组人血清白蛋白全球首个确证性临床研究达到研究终点
Project 3: A Recombinant Human Serum Albumin from Oryza Sativa (OsrHSA) Reached its Study Endpoints in a Phase 3 Pivotal Clinical Trial
杨代常 武汉禾元生物科技股份有限公司董事长
YANG Daichang , Chairman, Wuhan Healthgen Biotechnology Corp.
Project 5: Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-hodgkin’s Lymphoma: Real-world Data in Chinese Population
Project 6: Glecirasib in Combination with JAB-3312 (SHP2 inhibitor) in Advanced Solid Tumors Harboring KRAS G12C Mutation
丁瑜莉 北京加科思新药研发有限公司临床开发高级副总裁
DING Yuli , Senior Vice President, Clinical Development of Jacobio Pharmaceuticals
16:00 - 16:20
上海复星医药（集团）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
项目7：对比丁二酸复瑞替尼和克唑替尼在初治的ALK 阳性晚期或转移性NSCLC患者中的疗效和安全性
Project 7: Randomized, Open-label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
吴诸丽 复星医药全球研发中心高级副总裁、首席医学官（肿瘤）
WU Zhuli , Senior Vice President, CMO(oncology), Fosunpharma Global R&D Center
16:20 - 16:40
深圳微芯生物科技股份有限公司
Shenzhen Chipscreen Biosciences Co.,Ltd.
项目8：西格列他钠治疗代谢相关（非酒精性）脂肪性肝炎：一项随机、双盲、安慰剂对照的II期临床试验
Project 8:The Treatment of Chiglitazar for Metabolic Associated (Non-Alcoholic) Steatohepatitis: A randomized, Double-blind, Placebo-Controlled Phase II Clinical Trial
会务组联系人